HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Murthy on the Clinical Implications of Tucatinib Approval in HER2+ Breast Cancer

April 22nd 2020

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Tucatinib Lead Researcher Explains Significance of FDA Approval in HER2+ Breast Cancer

April 19th 2020

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Trastuzumab Biosimilar Ontruzant Enters US Oncology Market

April 15th 2020

Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

April 11th 2020

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm

April 10th 2020

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Indigenous American Ancestry May Be Associated With Increased Incidence of HER2+ Breast Cancer

April 9th 2020

An increased proportion of Indigenous American genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer.

Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast Cancer

April 9th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

Application of Neratinib in Breast Cancer Broadens

April 9th 2020

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast Cancer

April 8th 2020

Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast cancer.

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

April 7th 2020

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Dr. Crew on Updated Data With Margetuximab in HER2+ Breast Cancer

April 4th 2020

Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.

Dr. Lin on CNS Activity With HER2-Directed TKIs in HER2+ Breast Cancer

April 2nd 2020

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

Experts Explain Impact of Trastuzumab Deruxtecan Approval in HER2+ Breast Cancer

March 26th 2020

Faculty voice their opinion on the clinical utility of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Breast Cancer

March 25th 2020

The Japanese Ministry of Health, Labor, and Welfare has approved trastuzumab deruxtecan for the treatment of patients with HER2-positive unresectable or recurrent breast cancer who have had prior chemotherapy.

FDA Approves New Dose of Trastuzumab Biosimilar Ontruzant

March 24th 2020

The FDA has approved a 420-mg multidose vial of the biosimilar trastuzumab-dttb (SB3; Ontruzant).

Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer

March 20th 2020

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

Exciting New Options Emerge for HER2-Positive Breast Cancer

March 18th 2020

During a recent OncLive Peer Exchange®, experts in breast cancer research expressed optimism that new therapies would improve outcomes for patients with this challenging disease.

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

March 11th 2020

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Rugo on the Utility of Margetuximab in HER2+ Metastatic Breast Cancer

March 11th 2020

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Navigating the Changing Landscape in HER2-Positive Breast Cancer

March 9th 2020

The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD

NEXT PAGE
PREVIOUS PAGE